Tharimmune, Inc., (Nasdaq:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Matthew DeYoung Investor Relations and Media Argot Partners [email protected] Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that a plixorafenib abstract has been ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and ...

BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeuti ...

Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder ...

The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing.

A copy of the presentation materials will be added to the " Publications ” section of the Company's website at tscan.com once the presentation has concluded. About TScan Therapeutics, Inc.

Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting ...